MSCs

Weekly reads: New FDA guidance, brains, MSCs, senescence

human mouse marmoset brain

This week marked the release of new draft FDA guidance on cell and gene therapies. Is the FDA kind of like the guidance counselor at school or more like the principal? It probably depends on many factors. I also find it funny how pretty much everyone in academia and biotech industry works to be compliant …

Weekly reads: New FDA guidance, brains, MSCs, senescence Read More »

What are adult stem cells & their clinical applications?

mesenchymal cells

When someone uses the term “adult stem cells” you might think that simply means stem cells from adults. However, it’s not that simple. The goal of today’s post is to help you get all the key facts about adult stem cells. This includes the different types of adult stem cells and their clinical potential. What …

What are adult stem cells & their clinical applications? Read More »

Mesenchymal cells or MSCs: definition, stem cell fraction, & trial map

mesenchymal cells, MSCs, mesenchymal stem cells

I confess that I’m old enough to remember when the acronym MSC stood unambiguously for “mesenchymal stem cells”, but should it refer to a broader term like “mesenchymal cells”? The field has moved in that direction. I think that’s the best way to go too and I’ll explain why. The goal of today’s post is …

Mesenchymal cells or MSCs: definition, stem cell fraction, & trial map Read More »

Recommended reads: MSCs, vision, endothelial cells, more

wang et al 2020 science advances

What a year 2020 was, but there was still plenty of great science, which continues now in 2021 including published research like today’s recommended pieces and there’s one thread on MSCs today. The Niche new look, more features, and a Medical Advisory Board for 2021 Before we get to the recommended reads, note that 2021 …

Recommended reads: MSCs, vision, endothelial cells, more Read More »

Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval?

MSCs-mesenchymal-stem-cells-stromal-cells-small

Graft-versus-host disease (GVHD) is counterintuitive In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow …

Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval? Read More »

Weekly reads: FDA news, goosebump stem cells, MSCs, autophagy

Levy-et-al-MSCs-Science-Advances

Ready for the latest recommended weekly reads in the world of stem cells and the regenerative medicine space including a bunch of important new FDA posts & changes? This post has quite a lot on the FDA since it had a very big week with several new items of major importance to the cellular and regenerative …

Weekly reads: FDA news, goosebump stem cells, MSCs, autophagy Read More »

What is stromal vascular fraction or SVF?

SVF2

When people discuss “fat stem cells” they usually mean something called “stromal vascular fraction” or SVF. While references to fat or adipose stem cells can sometimes mean non-SVF materials, these days adipose SVF gets the most attention. But, does anyone have a clear picture of this biologic? Fortunately, it’s starting to come more into focus …

What is stromal vascular fraction or SVF? Read More »

4 possible roles for stem cell therapy besides cell replacement

stem-cells-drug-delivery

Historically, the main route of proposed healing via stem cell therapy was cell replacement. In this way of thinking the transplanted cells engrafted (took up home) in the patient’s tissue and replaced dead or diseased cells. However, interest continues to grow in other possible modes of healing by stem cells that don’t rely on cell …

4 possible roles for stem cell therapy besides cell replacement Read More »

New Interview with FDA on Key Stem Cell Regulatory Issues & Its Own Research

FDA3

It’s been a seemingly rather quiet year on the regulatory front in the US when it comes to direct-to-consumer stem cell interventions even as the number of dubious stem cell clinics continues to skyrocket. I requested an interview with the FDA to cover the key pressing issues in this arena. I want to thank the …

New Interview with FDA on Key Stem Cell Regulatory Issues & Its Own Research Read More »